Celltrion, Inc.
068270
Kedudukan dalam Saham
#720
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
Harga Saham
$146.63
Modal Pasaran
$33.44B
Perubahan (1 hari)
-1.52%
Perubahan (1 tahun)
23.60%
Negara
KR
Perdagangan Celltrion, Inc. (068270)
Kategori
Healthcare
Bilangan saham terbitan bagi Celltrion, Inc. (068270)
Bilangan saham terbitan setakat June 2026: 233.25M
Menurut laporan kewangan terkini dan harga saham Celltrion, Inc., bilangan saham terbitan semasa ialah 233.25M. Pada akhir December 2024, syarikat mempunyai 217.00M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Celltrion, Inc. (068270) dari 2007 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| 2026 (TTM) | 233.25M | 0.99% |
| 2025 | 230.96M | 6.43% |
| 2024 | 217.00M | 52.04% |
| 2023 | 142.73M | 3.35% |
| 2022 | 138.10M | -4.67% |
| 2021 | 144.87M | 0.15% |
| 2020 | 144.65M | 0.14% |
| 2019 | 144.44M | -0.05% |
| 2018 | 144.52M | 0.11% |
| 2017 | 144.35M | 0.26% |
| 2016 | 143.98M | 2.91% |
| 2015 | 139.90M | 2.76% |
| 2014 | 136.14M | -0.01% |
| 2013 | 136.16M | -0.96% |
| 2012 | 137.49M | -0.65% |
| 2011 | 138.39M | 4.84% |
| 2010 | 132.00M | 8.34% |
| 2009 | 121.83M | 3.78% |
| 2008 | 117.40M | 1,578.29% |
| 2007 | 7.00M | 0.00% |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 253.90M | 8.86% |
US
|
|
| 396.00M | 69.78% |
US
|
|
| 478.91M | 105.33% |
AU
|
|
| 0.00 | -100.00% |
BE
|
|
| 62.19M | -73.34% |
NL
|
